Anti- ANGPTL3 antibody - Luye Pharma/ Shandong Boan Biotechnology
Latest Information Update: 28 Jan 2024
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Antibodies; Antihyperlipidaemics
- Mechanism of Action ANGPTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercholesterolaemia